<DOC>
	<DOCNO>NCT00800319</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics , safety , tolerability RDC-0313 follow oral administration .</brief_summary>
	<brief_title>ALK33-001 : A Study RDC-0313 Administered Healthy Adults</brief_title>
	<detailed_description>This single-center , randomize , double-blind , ascend dose , placebo control study . Dosing sequence consist 5 administration oral solution either ascend dos RDC-0313 volume-match placebo . Dosing cohort stagger allow blind safety review occur prior dose next cohort . Subjects admit facility morning dose , require fast overnight prior study drug administration . They discharge facility 36-hour postdose assessment complete .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>ALKS-33</mesh_term>
	<criteria>18 65 year age Body mass index 1930 kg/m2 screen If subject female childbearing potential , must agree use acceptable method contraception If subject male , must agree reduce risk female partner become pregnant Pregnancy and/or currently breastfeed Clinically significant medical condition observe abnormality Clinically significant illness within 30 day first study drug administration History opioid dependence Positive urine toxicological screen marijuana , cocaine , amphetamine , opioids , barbiturate , benzodiazepine Positive resolut serology test perform screen Use alcohol , caffeine , xanthinecontaining product Tobacco use within 90 day first study drug administration Participation clinical trial within 30 day screen Requirement special diet vegetarian , significant food allergy intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Alcohol dependence</keyword>
	<keyword>Opioid antagonist</keyword>
	<keyword>RDC-0313</keyword>
</DOC>